279 related articles for article (PubMed ID: 35273654)
21.
Lin W; Chen X; Chen T; Liu J; Ye Y; Chen L; Qiu X; Chia-Hsien Cheng J; Zhang L; Wu J; Qiu S
DNA Cell Biol; 2020 Jun; 39(6):1000-1011. PubMed ID: 32282241
[TBL] [Abstract][Full Text] [Related]
22. Bioinformatic Analysis and Clinical Case Studies Identify CD276 as a Promising Diagnostic Biomarker for Clear Cell Renal Cell Carcinoma.
Zhang Z; Xu J; Song Z; Zhang J; Lin Y; Ouyang J
Cancer Control; 2024; 31():10732748241250181. PubMed ID: 38669187
[TBL] [Abstract][Full Text] [Related]
23. ID1 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Deterioration of Clear Cell Renal Cell Carcinoma.
Qiu X; Gu Y; Ni Y; Li Q
Biomed Res Int; 2020; 2020():2064582. PubMed ID: 33178820
[TBL] [Abstract][Full Text] [Related]
24. A novel 10 glycolysis-related genes signature could predict overall survival for clear cell renal cell carcinoma.
Xing Q; Zeng T; Liu S; Cheng H; Ma L; Wang Y
BMC Cancer; 2021 Apr; 21(1):381. PubMed ID: 33836688
[TBL] [Abstract][Full Text] [Related]
25. BAI1 as a Prognostic Marker of Clear Cell Renal Cell Carcinoma (ccRCC).
Pesta M; Travnicek I; Kulda V; Windrichova J; Rezackova H; Houfkova K; Macanova T; Bendova B; Nestorova A; Hes O; Hora M; Topolcan O; Polivka J
Anticancer Res; 2021 Sep; 41(9):4463-4470. PubMed ID: 34475070
[TBL] [Abstract][Full Text] [Related]
26. Low expression of SLC34A1 is associated with poor prognosis in clear cell renal cell carcinoma.
Qiu J; Wang Z; Xu Y; Zhao L; Zhang P; Gao H; Wang Q; Xia Q
BMC Urol; 2023 Mar; 23(1):45. PubMed ID: 36978048
[TBL] [Abstract][Full Text] [Related]
27. The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma.
Xu WH; Shi SN; Wang J; Xu Y; Tian X; Wan FN; Cao DL; Qu YY; Zhang HL; Ye DW
Med Sci Monit; 2019 Dec; 25():9458-9470. PubMed ID: 31825950
[TBL] [Abstract][Full Text] [Related]
28. High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.
Zhu ZP; Lin LR; Lv TD; Xu CR; Cai TY; Lin J
Oncol Rep; 2020 Nov; 44(5):2056-2066. PubMed ID: 33000227
[TBL] [Abstract][Full Text] [Related]
29. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
[TBL] [Abstract][Full Text] [Related]
30. Prognosis of clear cell renal cell carcinoma (ccRCC) based on a six-lncRNA-based risk score: an investigation based on RNA-sequencing data.
Zeng JH; Lu W; Liang L; Chen G; Lan HH; Liang XY; Zhu X
J Transl Med; 2019 Aug; 17(1):281. PubMed ID: 31443717
[TBL] [Abstract][Full Text] [Related]
31. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
[TBL] [Abstract][Full Text] [Related]
32. A novel risk signature based on liquid-liquid phase separation-related genes reveals prognostic and tumour microenvironmental features in clear cell renal cell carcinoma.
Lu Q; Xi P; Xu S; Zhang Z; Gong B; Liu J; Zhu Q; Sun T; Zhu S; Chen R
Aging (Albany NY); 2024 Mar; 16(7):6118-6134. PubMed ID: 38546385
[TBL] [Abstract][Full Text] [Related]
33. Fifteen hub genes associated with progression and prognosis of clear cell renal cell carcinoma identified by coexpression analysis.
Wang Y; Chen L; Wang G; Cheng S; Qian K; Liu X; Wu CL; Xiao Y; Wang X
J Cell Physiol; 2019 Jul; 234(7):10225-10237. PubMed ID: 30417363
[TBL] [Abstract][Full Text] [Related]
34. A cluster of metabolism-related genes predict prognosis and progression of clear cell renal cell carcinoma.
Liu M; Pan Q; Xiao R; Yu Y; Lu W; Wang L
Sci Rep; 2020 Jul; 10(1):12949. PubMed ID: 32737333
[TBL] [Abstract][Full Text] [Related]
35. Differentially expressed autophagy-related genes are potential prognostic and diagnostic biomarkers in clear-cell renal cell carcinoma.
Wan B; Liu B; Yu G; Huang Y; Lv C
Aging (Albany NY); 2019 Oct; 11(20):9025-9042. PubMed ID: 31626592
[TBL] [Abstract][Full Text] [Related]
36. Wiskott-Aldrich syndrome gene as a prognostic biomarker correlated with immune infiltrates in clear cell renal cell carcinoma.
Ding G; Wang T; Liu S; Zhou Z; Ma J; Wu J
Front Immunol; 2023; 14():1102824. PubMed ID: 37122750
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm.
Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y
Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223
[TBL] [Abstract][Full Text] [Related]
38. 53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database.
Tang F; Lu Z; He C; Zhang H; Wu W; He Z
BMC Cancer; 2021 May; 21(1):638. PubMed ID: 34051738
[TBL] [Abstract][Full Text] [Related]
39. Microenvironment-associated gene HSD11B1 may serve as a prognostic biomarker in clear cell renal cell carcinoma: a study based on TCGA, RT‑qPCR, Western blotting, and immunohistochemistry.
Han D; Yu Z; Zhang H; Liu H; Wang B; Qian D
Bioengineered; 2021 Dec; 12(2):10891-10904. PubMed ID: 34845968
[TBL] [Abstract][Full Text] [Related]
40. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
